CVS acquisition of Aetna may not face antitrust challenges

Amy Baxter | | Health Exec | Policy & Regulations

U.S. antitrust enforcers might not move to block CVS Health’s acquisition of health insurance company Aetna, Bloomberg reported. The news, which was fueled from a report by Reorg Research, spiked shares of both companies last week.

Justice Department staff are expected to support approval of the $69 billion deal, which was announced in December 2017 and approved by shareholders of both companies in March.

Read the full story below:

CVS, Aetna Shares Jump on Report About Deal's Antitrust Status

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Trump administration halts public communications from health agencies
Trump signs executive order to withdraw U.S. from the World Health Organization
DOJ sues Walgreens for allegedly filling ‘millions’ of illegal prescriptions
Another insurer sues CMS over star ratings, citing contractor error
Biden chooses semaglutide for next round of Medicare price negotiations—Trump gets final say
DEA wants to permanently anchor some COVID-era prescription regulations

Around the web

Cardiovascular Business
Biden chooses semaglutide for next round of Medicare price negotiations—Trump gets final say

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

AI in Healthcare
4 ways HHS plans to help shape a national strategy for healthcare AI

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.

Cardiovascular Business
FDA announces recall after Philips heart monitor software failed to send alerts—multiple deaths reported

Philips is recalling the software associated with its Mobile Cardiac Outpatient Telemetry devices after certain high-risk ECG events were never routed to trained cardiology technicians as intended. The issue, which lasted for two years, has been linked to more than 100 injuries.